



# Mirum Scientific Affairs Request for Proposals (RFP)

Mirum is committed to advancing the science of rare diseases in order to positively impact patients' lives. Through its externally sponsored research program (ESR), Mirum supports independent research efforts conducted by external investigators within its therapeutic areas of interest.

## Program Overview

Mirum is announcing a new grant opportunity through a Request for Proposals (RFP) to support innovative research initiatives focused on understanding the potential impact of bile acid reduction on liver health in patients with Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis (PFIC). Proposals will be eligible for up to \$350,000 (USD) in funding, plus applicable indirect costs (up to 30%). Submission of a Letter of Intent (LOI) is required as the first step in the application process via the **Mirum ESR Portal**. Proposals are encouraged to be multi-disciplinary and to include collaboration with patient advocacy groups.

**Specific Area of Interest:** Mirum is interested in supporting research initiatives including, but not limited to, the following areas:

1. Mechanistic insights into how bile acid reduction may influence liver health (e.g., liver fibrosis), disease progression, and outcomes in ALGS or PFIC.
2. Clinical studies that explore how novel biomarkers may predict or explain overall progression of disease in ALGS or PFIC.
3. Innovative methodologies or technologies for monitoring and assessing bile acid levels, including intrahepatic bile acid levels, and their relationship to overall liver health.

## KEY DATES



## Budget Considerations

The total available funding for this RFP is \$350,000 USD for one year, plus allowable indirect costs (up to 30%). Proposals that include a request for second-year funding may be considered, for an additional \$350,000 (USD). Requests for second-year funding should be milestone-driven and justified by clearly defined go/no-go criteria.

## Available Research Resources

To support this RFP, samples from Mirum's maralixibat clinical trials in ALGS and PFIC may be made available. Investigators may request information on available samples by contacting [ESR@mirumpharma.com](mailto:ESR@mirumpharma.com) to assess overall project feasibility. If a study drug is requested, Mirum may provide it only in countries where the product has received regulatory approval and is commercially available.

### Eligibility

1. Grant funding is limited to organizations. Applications from individuals or independent medical practice groups - those not affiliated with a hospital, university, or professional society - will not be considered.
2. The Principal Investigator (PI) must hold a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with MS or PhD), or a professional degree in Pharmacy, Physiotherapy, or Social Work.
3. The PI must be an employee of the requesting organization.
4. The requesting organization must be legally able to receive funds directly from Mirum Pharmaceuticals, Inc. Applicants should confirm this with their institution before applying. Grants awarded to organizations found ineligible to accept direct funding from Mirum Pharmaceuticals, Inc. may be withdrawn.

As the study sponsor, the PI will be responsible for ensuring compliance with all laws and regulations applicable to research sponsors, including meeting local requirements and obtaining all necessary regulatory approvals before initiating the study. A single sponsor should be identified for contract negotiations and Institutional Review Board (IRB)/ independent ethics committee (IEC) review.

## Application and Review Process

To be considered for funding under the Mirum RFP program, applicants must submit an LOI that includes a concise overview of the proposed project (should not exceed 2 pages). Preliminary data are welcome but not required. All LOIs must be submitted through the **Mirum ESR portal**. LOIs are due March 23, 2026, by 11:59 PM Pacific Standard Time (PST). All submitted LOIs will undergo rigorous review by an internal committee.

Investigators whose LOIs receive the highest scores will be invited to submit a full proposal. All invited full proposals will undergo review by an independent external committee of experts in relevant scientific and clinical disciplines, as well as representatives from patient advocacy groups. Proposals will be evaluated based on scientific merit, innovation, operational feasibility, and alignment with program objectives. Final funding decisions will be made following completion of the external review process.

### The LOI should include the following:

- Clear scientific objectives and endpoints, based on sound scientific hypotheses;
- Appropriate, defined, and specific data collection/evaluation methods;
- Assessment of feasibility of completion of the project within 18 months, and dissemination plan.

## RFP Timeline



### No Guarantee of Funding

Mirum reserves the right to approve or decline any application at its sole discretion. Submission of a LOI or full proposal does not guarantee funding. Awards will be granted for research purposes only; expenses related to routine medical care or other non-research-related activities will not be supported.

Mirum discourages proposals that solely request study drug supply or funding for screening-related costs. Approval of awards will depend on the availability of funds and the scientific merit and completeness of the submitted proposals. Awards will be made solely on the quality of the research and its alignment with the objectives of this funding opportunity.

Distribution of the funds is contingent upon a fully executed funding agreement and submission of the Final Protocol, IRB/IEC approval documentation, and any applicable regulatory approvals, exemptions, or waivers.

### No Inducement or Reward

Mirum's approval of funding awards is made independently of any past, present, or future business relationships or referrals between the parties. Awards are not provided, directly or indirectly, as an inducement or reward for the purchase, utilization, recommendation, or formulary placement of any Mirum product.

Except for the use of a Mirum product in an approved research project, award recipients are not required to purchase, prescribe, or recommend any Mirum products as a condition of funding.

### Questions

If you have questions regarding this RFP, please direct them in writing to Shannon Vandriel: [shannon.vandriel@mirumpharma.com](mailto:shannon.vandriel@mirumpharma.com) or Douglas Mogul: [douglas.mogul@mirumpharma.com](mailto:douglas.mogul@mirumpharma.com)